Fosmanogepix (Cat.No:I017638) is a novel antifungal agent under investigation for the treatment of invasive fungal infections. It belongs to the class of nucleoside inhibitors and exhibits broad-spectrum activity against a range of fungal pathogens, including Candida and Aspergillus species. Clinical trials are ongoing to evaluate its efficacy and safety for clinical use.
| Catalog Number | I017638 |
| CAS Number | 2091769-17-2 |
| Molecular Formula | C₂₂H₂₁N₄O₆P |
| Purity | 95% |
| IUPAC Name | [2-amino-3-[3-[[4-(pyridin-2-yloxymethyl)phenyl]methyl]-1,2-oxazol-5-yl]pyridin-1-ium-1-yl]methyl hydrogen phosphate |
| InChI | InChI=1S/C22H21N4O6P/c23-22-19(4-3-11-26(22)15-31-33(27,28)29)20-13-18(25-32-20)12-16-6-8-17(9-7-16)14-30-21-5-1-2-10-24-21/h1-11,13,23H,12,14-15H2,(H2,27,28,29) |
| InChIKey | JQONJQKKVAHONF-UHFFFAOYSA-N |
| SMILES | C1=CC=NC(=C1)OCC2=CC=C(C=C2)CC3=NOC(=C3)C4=C([N+](=CC=C4)COP(=O)(O)[O-])N |
| Reference | [1]. Shaw KJ, et al. In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus. Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00523-18.<br>[2]. Gebremariam T, et al. APX001 Is Effective in the Treatment of Murine Invasive Pulmonary Aspergillosis. Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01713-18. |
